Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
82.54
-0.76 (-0.91%)
At close: Jul 31, 2026, 4:00 PM EDT
82.57
+0.03 (0.04%)
After-hours: Jul 31, 2026, 7:34 PM EDT
Halozyme Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Halozyme Therapeutics stock has a consensus rating of "Buy" and an average price target of $86.89. The average 1-year stock price forecast is 5.27% higher than the current stock price, while the lowest is $70 (-15.19%) and the highest is $96 (+16.31%).
Price Target: $86.89 (+5.27%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Halozyme Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 9 | 9 | 9 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $95 | Buy | Reiterates | $95 | +15.10% | Jul 21, 2026 |
| Goldman Sachs | Goldman Sachs | Sell Maintains $57 | Sell | Maintains | $57 | -30.94% | Jun 15, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $93 | Buy | Maintains | $93 | +12.67% | Jun 15, 2026 |
| Wells Fargo | Wells Fargo | Hold Reiterates $75 | Hold | Reiterates | $75 | -9.13% | Jun 15, 2026 |
Unknown Analyst J.P. Morgan No rating | J.P. Morgan | Hold Maintains $70 | Hold | Maintains | $70 | -15.19% | May 20, 2026 |
Financial Forecast
Revenue This Year
1.77B
from 1.40B
Increased by 26.57%
Revenue Next Year
2.00B
from 1.77B
Increased by 13.40%
EPS This Year
8.10
from 4.15
Increased by 95.19%
EPS Next Year
9.99
from 8.10
Increased by 23.27%
EPS and Forward PE are based on non-GAAP adjusted numbers.